2RT Presentation Professor Robyn H Guymer Today 15 Sept 2022
ASX Announcement General AlphaRET
15 Sept, 2022
AGM Date and Directors Nominations
ASX Announcement General iTrack Molteno3 AlphaRET
14 Sept, 2022
EYE 2RT Webinar Prof Guymer
ASX Announcement General iTrack Molteno3 AlphaRET
9 Sept, 2022
EYE FY22 Appendix 4G & Governance Statement
ASX Announcement General iTrack Molteno3 AlphaRET
26 Aug, 2022
EYE FY22 Results Presentation
ASX Announcement General iTrack Molteno3 AlphaRET
26 Aug, 2022
EYE FY22 Results Announcement
ASX Announcement General iTrack Molteno3 AlphaRET
26 Aug, 2022
EYE FY22 Appendix 4E & Annual Report
ASX Announcement General iTrack Molteno3 AlphaRET
26 Aug, 2022
Nova Eye Medical Launches iTrack Advance
ASX Announcement General iTrack Molteno3 AlphaRET
8 June, 2022
2RT Pivotal Study and Regulatory Pathway Presentation
ASX Announcement General AlphaRET
3 May, 2022
Nova Eye Medical Announces Regulatory Pathway for AlphaRET 2RT in the USA
ASX Announcement General AlphaRET
3 May, 2022
Investor Presentation Half Year Results 31 December 2021
ASX Announcement General iTrack Molteno3 AlphaRET
17 Feb, 2022
Global Revenue of A$6.5m for 6 Months Ended 31 Dec 2021
ASX Announcement General iTrack Molteno3 AlphaRET
17 Feb, 2022
Half Yearly Report and Accounts
ASX Announcement General iTrack Molteno3 AlphaRET
17 Feb, 2022
Presentation - Reducing Progression Rate of Age-Related Macular Degeneration
ASX Announcement General AlphaRET
21 Dec, 2021
5-Year Efficacy and Safety of iTrack™ to be Spotlighted at ESCRS 2021
ASX Announcement General iTrack Molteno3 AlphaRET
7 Oct, 2021
For investor enquires please contact:
Mark Flynn
Nova Eye Medical Limited
W +61 416 068 733
mflynn@nova-eye.com
This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More
The cookies do not store any personalised information. Learn More